Streetbeat News

Earnings

FLGT

Fulgent Genetics, Inc. (FLGT) reported Q3 earnings of $0.31 per share, surpassing the Zacks Consensus Estimate of a loss of $0.19 per share. This marks a significant improvement from a loss of $0.39 per share a year ago.

Portfolio Pulse from

November 08, 2024 | 2:30 pm

RIVN

Rivian missed Q3 expectations, but strategic moves suggest potential improvement. Investors are considering whether to buy now or wait for clearer signs of recovery.

Portfolio Pulse from

November 08, 2024 | 2:30 pm

DIBS

1stdibs.com (DIBS) reported a Q3 loss of $0.15 per share, missing the Zacks Consensus Estimate of a $0.13 loss. This is a larger loss compared to $0.08 per share a year ago.

Portfolio Pulse from

November 08, 2024 | 2:30 pm

PARAA

Paramount Global (PARAA) reported Q3 earnings of $0.49 per share, surpassing the Zacks Consensus Estimate of $0.40 per share and improving from $0.30 per share a year ago.

Portfolio Pulse from

November 08, 2024 | 2:30 pm

APYX

Apyx Medical (APYX) reported a Q3 loss of $0.14 per share, slightly better than the Zacks Consensus Estimate of a $0.15 loss, but worse than the $0.13 loss per share from a year ago. The company also lagged in revenue estimates.

Portfolio Pulse from

November 08, 2024 | 2:30 pm

UG

United-Guardian, Inc. (NASDAQ:UG) reported increased earnings for the third quarter and the first nine months of 2024. Sales rose from $8.28 million in 2023 to $9.71 million in 2024, and net income increased from $1.84 million to $2.75 million. The third quarter sales were steady, but net income rose from $626,756 to $865,484.

Portfolio Pulse from

November 08, 2024 | 2:15 pm

ECNCF

ECN Capital Corp. (ECNCF) held its Q3 2024 earnings conference call, discussing financial performance and strategic updates. Key participants included executives from ECN and its subsidiaries, Triad Financial and Source One.

Portfolio Pulse from

November 08, 2024 | 2:15 pm

CVSI

CV Sciences, Inc. will announce its third quarter 2024 financial results on November 14, 2024. The company specializes in hemp extracts and natural ingredients. A conference call with investors is scheduled for the same day.

Portfolio Pulse from

November 08, 2024 | 2:15 pm

NVZMY

Novonesis, a company formed from Chr. Hansen and Novozymes, is showing promising growth with a 9% increase in organic sales for 9M24. Despite a decrease in P/E ratio from 40x to 33x, the company remains overvalued. Growth is driven by new products and emerging markets, but risks include reliance on GDP-like growth in core markets and volatility in energy/bioenergy sectors.

Portfolio Pulse from

November 08, 2024 | 2:15 pm

IGMS

IGM Biosciences, Inc. (IGMS) reported a Q3 loss of $1.01 per share, which was larger than the Zacks Consensus Estimate of a $0.82 loss. However, the company exceeded revenue expectations.

Portfolio Pulse from

November 08, 2024 | 2:15 pm